FDA Submission Update for ALTACE (Ramipril) by King Pharmaceuticals
King Pharmaceuticals has submitted a supplemental application for ALTACE (Ramipril) with a standard review priority.
Company
King Pharmaceuticals
Signal assessment
Signal strength
moderate
Confidence level
moderate
Why it matters
The submission of a supplemental application for ALTACE by King Pharmaceuticals could lead to new indications or formulations, potentially reshaping the competitive landscape for ACE inhibitors. Portfolio teams need to evaluate the implications for existing products in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any announcements regarding the approval status of the supplemental application.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.